Telomir Pharmaceuticals, Inc. - Common Stock (NQ:TELO)

1.405 -0.055 (-3.77%)

Streaming Delayed Price Updated: 11:16 AM EST, Dec 29, 2025 Add to My Watchlist

Price and Volume

Volume	89,703
Open	1.430
Bid (Size)	1.400 (5,900)
Ask (Size)	1.410 (500)
Prev. Close	1.460
Today's Range	1.400 - 1.455
52wk Range	1.120 - 5.400
Shares Outstanding	34,380,971
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Favorable IND-Enabling GLP Safety Results for Telomir-1

December 18, 2025

Via Investor Brand Network

Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development

December 18, 2025

Via ACCESS Newswire

Performance

YTD	-65.5%	-65.5%
1 Month	+4.9%	+4.9%
3 Month	+4.9%	+4.9%
6 Month	+12.4%	+12.4%
1 Year	-69.7%	-69.7%

More News

Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells

November 25, 2025

Via ACCESS Newswire

TELO Stock Jumps Pre-market After Early Study Results Show Leukemia Cell Death ↗

November 21, 2025

Via Stocktwits

Why Telomir Pharmaceuticals Stock Is Rising 40% Premarket Today ↗

October 09, 2025

Via Stocktwits

Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells

November 21, 2025

Via ACCESS Newswire

Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line

November 12, 2025

Via ACCESS Newswire

Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo

October 23, 2025

Via ACCESS Newswire

Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth

October 21, 2025

Via ACCESS Newswire

Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer

October 14, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 09, 2025

Via Benzinga

Thursday's after hours session: top gainers and losers ↗

October 09, 2025

Via Chartmill

Telomir Pharmaceuticals Touts Promising Action From Its Lead Breast Cancer Drug ↗

October 09, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 09, 2025

Via Benzinga

Which stocks are moving before the opening bell on Thursday? ↗

October 09, 2025

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 09, 2025

Via Benzinga

Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells

October 09, 2025

Via ACCESS Newswire

Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket ↗

October 09, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 08, 2025

Via Benzinga

What's going on in today's after hours session ↗

October 08, 2025

Via Chartmill

Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance

October 07, 2025

Via ACCESS Newswire

Stock Market Today: Dow Jones, Nasdaq Futures Slip Amid Delay In Trade Deficit Data During Shutdown—Trilogy Metals, AMD, Applovin In Focus ↗

October 07, 2025

Via Benzinga

Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket ↗

October 07, 2025

Via Benzinga

McCormick, Telomir Pharmaceuticals And 3 Stocks To Watch Heading Into Tuesday ↗

October 07, 2025

Via Benzinga

What's Behind The Sharp 39% After-Hours Rally In Telomir Pharmaceuticals? ↗

October 06, 2025

Via Benzinga

Frequently Asked Questions

Is Telomir Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Telomir Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Telomir Pharmaceuticals, Inc. - Common Stock trade on?

Telomir Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Telomir Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Telomir Pharmaceuticals, Inc. - Common Stock is TELO on the Nasdaq Stock Market

What is the current price of Telomir Pharmaceuticals, Inc. - Common Stock?

The current price of Telomir Pharmaceuticals, Inc. - Common Stock is 1.405

When was Telomir Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Telomir Pharmaceuticals, Inc. - Common Stock was at 12/29/25 11:16 AM ET

What is the market capitalization of Telomir Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Telomir Pharmaceuticals, Inc. - Common Stock is 48.31M

How many shares of Telomir Pharmaceuticals, Inc. - Common Stock are outstanding?

Telomir Pharmaceuticals, Inc. - Common Stock has 48M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.